Companies · Biotechnology

StemoniX, Inc.

Maple Grove · Biotechnology

Diligence memoA one-page analyst read on StemoniX, Inc. — recommendation, valuation, rhythm, risks.
$14.6M
Total raised · real
7
Rounds
0.0×
Latest step-up
Top 38%
Sector rank · raised
Series A
Latest stage · inferred · Mon May 04 2020 00:00:00 GMT+0000 (Coordinated Universal Time)

StemoniX, Inc. looks under-valued against its niche peers and is dormant on financing cadence.

Synthesized from the figures below est. — every claim rests on a number shown on this page. Valuation uses the biotech sector profile.

Analyst read est. — computed against this company's niche peers in the same era. Inputs shown; not a quoted figure.

Under-valued
  • Modeled value is 0.02× the median modeled value of Series A Biotechnology companies in 2019–2021 (216 peers) — value vs value, same stage and era.
Dormant
  • Last raise 6.2 yr ago; this sector typically re-raises about every 14 months.
  • Silent for over 3× the sector's normal cadence.
Leadership

No named principal in this company's public records yet — see all operators below.

Explore how these operators interlock with other companies in the operator network.

Where it sits in Biotechnology

StemoniX, Inc. is one of 4291 Biotechnology companies tracked from Maple Grove. By capital raised it ranks mid-pack (ahead of 63% of sector peers), and in the long tail by modeled valuation est..

Ranking is computed against this company's own sector cohort — reported capital is fact; valuation tiers are modeled.

As reported in public records reported — not modeled.

US
Jurisdiction
Rule 506(b)
Reg D exemption
3
Investors (latest)
2020-05-04
First sale
Amount raised vs valuation, by round

Solid bars are reported offering amounts reported; hatched bars are the modeled post-money valuation est. — both on one shared scale so you can read raise-vs-worth at each round directly. Use the toggles to overlay data labels and the niche-peer / market average value lines.

Amount raised · realModeled valuation · estCumulative funded · real
$0$50M$100M$150M$200MSeed · 2015-12-29 Raised $1.1M (real) Modeled valuation $51M (est)Seed2015Seed · 2016-07-22 Raised $2.5M (real) Modeled valuation $111M (est)Seed2016Pre-Seed · 2016-07-22 Raised $523K (real) Modeled valuation $29M (est)Pre-Seed2016Seed · 2017-02-24 Raised $2.4M (real) Modeled valuation $107M (est)Seed2017Seed · 2017-07-01 Raised $3.0M (real) Modeled valuation $133M (est)Seed2017Series A · 2017-10-24 Raised $4.9M (real) Modeled valuation $178M (est)Series A2017Series A · 2017-10-24 Raised $4.4M (real) Modeled valuation $159M (est)Series A2017Series A · 2018-08-08 Raised $1.4M (real) Modeled valuation $52M (est)Series A2018Series A · 2019-09-27 Raised $2.1M (real) Modeled valuation $75M (est)Series A2019Series A · 2020-05-04 Raised $100K (real) Modeled valuation $3.6M (est)Series A2020+$2.5M+$523K+$2.4M+$3.0M+$4.9M+$4.4M+$1.4M+$2.1M+$100KCumulative $22M

The line shows cumulative reported funding over the period; + labels show new capital added between points when there is room. Toggle on-bar figures, plus the niche-peer and market averages, to read this company against its cohort. Benchmarks are modeled medians.

Financing ladder & sequence gaps
Seed$1.1M · 2015
Seed extension$2.5M · 2016
Bridge · Seed-stage$523K · 2016smaller follow-on
Seed extension$2.4M · 2017
Seed extension$3.0M · 2017
Series A$4.9M · 2017
Series A extension$4.4M · 2017
Series A extension$1.4M · 2018
Series A extension$2.1M · 2019
Series A extension$100K · 2020

Stages are modeled from round size (public records carry no series label). Ladder is contiguous — every modeled rung has a record.

Modeled valuation trajectory
$3.6M
Base estimate est.
$109K
Conservative case
$19.7M
Upside case
$455K
Modeled post-money

Round size and date are reported; the stage label is inferred from round size (latest is Series Aa $4.0M–$15M round). Valuation is modeled from stage benchmarks scaled by the biotech sector profile. Directional, not a quoted figure.

Seed · modeled $50.6M · 2015-12-292015Seed · modeled $111.0M · 2016-07-22Pre-Seed · modeled $28.9M · 2016-07-22Seed · modeled $107.1M · 2017-02-24Seed · modeled $133.2M · 2017-07-01Series A · modeled $178.2M · 2017-10-24Series A · modeled $158.7M · 2017-10-24Series A · modeled $51.7M · 2018-08-08Series A · modeled $74.7M · 2019-09-27Series A · modeled $3.6M · 2020-05-042020
Model inputs · modeled:benchmark-stage-stepup-v1
22%
Dilution assumption
Implied ownership sold in the financing.
44%
Survival probability
24% low · 60% high
1.62×/yr
Annual markup
2.04×/yr upside case
6.0 yr
Elapsed time used
6.2 yr actual, capped for stale marks
biotech
Sector profile
Adjusts growth and survival by industry.
Financing rhythm
6 mo
Avg between rounds
$3.4M/yr
Capital velocity
10.5 yr
On record since
2015
First round
10
Rounds on file
How it compares to the market

Benchmarked against 4291 companies in Biotechnology. Each bar is a median (the middle company, not an average — outliers don't skew it). Two yardsticks: real money raised (reported on Form D) and modeled value (our estimate est.). These are whole-sector medians across all stages, except the per-stage row.

Total raised — vs sector median (real $, all stages) 2.0× above median
This company$14.6M
Sector median$7.2M
Latest round — vs other Series A rounds in sector (real $, this stage) 0.0× of median
This company$100K
Sector median$5.4M
Modeled value — vs sector median (estimate, all stages) 0.1× of median
This company$3.6M
Sector median$64.2M

Raised more than 63% of sector peers (real $). Modeled value above 8% of peers (estimate).

Niche peers — same stage & era

A tighter cohort than the sector chart above — only companies at the same stage (Series A) that last raised in the same ~3-year era, ranked by modeled value est. (not money raised). This is the exact set the analyst read compares against, so a like-for-like cohort is what makes "over/under-valued" meaningful. This company ranks #216 of 216.

This companyCohort peer
$1.0M$10.0M$100.0M$1.0B$10.0M$100.0MCapital raised (log)TRACT Therapeutics, Inc. · Series A Raised $15.0M · modeled $542.3M (est)Arrakis Therapeutics, Inc. · Series A Raised $28.2M · modeled $542.3M (est)TechAccel, LLC · Series A Raised $15.0M · modeled $541.9M (est)Trident Labs, Inc. · Series A Raised $14.0M · modeled $506.1M (est)Meissa Vaccines Inc · Series A Raised $15.2M · modeled $503.1M (est)Vibe Bioscience Ltd. · Series A Raised $13.9M · modeled $501.1M (est)Trovagene, Inc. · Series A Raised $45.3M · modeled $488.0M (est)Equinox, Inc. · Series A Raised $34.7M · modeled $485.2M (est)Taiga Biotechnologies, Inc. · Series A Raised $37.9M · modeled $484.6M (est)Aruna Biomedical Inc · Series A Raised $22.4M · modeled $480.5M (est)Vibe Bioscience Corp · Series A Raised $13.7M · modeled $476.8M (est)Adarza BioSystems, Inc. · Series A Raised $31.5M · modeled $461.9M (est)StemoniX, Inc. (this company) Raised $14.6M · modeled $3.6M (est)StemoniX, Inc.
CompanyStageRaised · realValue · estvs peer med.
TRACT Therapeutics, Inc.Series A$15.0M$542.3M3.00×
Arrakis Therapeutics, Inc.Series A$28.2M$542.3M3.00×
TechAccel, LLCSeries A$15.0M$541.9M3.00×
Trident Labs, Inc.Series A$14.0M$506.1M2.80×
Meissa Vaccines IncSeries A$15.2M$503.1M2.78×
Vibe Bioscience Ltd.Series A$13.9M$501.1M2.77×
Trovagene, Inc.Series A$45.3M$488.0M2.70×
Equinox, Inc.Series A$34.7M$485.2M2.68×
Taiga Biotechnologies, Inc.Series A$37.9M$484.6M2.68×
Aruna Biomedical IncSeries A$22.4M$480.5M2.66×
Vibe Bioscience CorpSeries A$13.7M$476.8M2.64×
Adarza BioSystems, Inc.Series A$31.5M$461.9M2.56×
StemoniX, Inc. this companySeries A$14.6M$3.6M0.02×
Full financing history

Stage is inferred from round size est., not reported on the filing — a round's dollar size maps to a bucket: Pre-Seed <$1.0M · Seed $1.0M–$4.0M · Series A $4.0M–$15M · Series B $15M–$40M · Series C $40M–$100M · Series D+ $100M–$400M · Growth/Late >$400M.

StageAmount · realAnnouncedPost-money · estValue · estConf.
Seed$1.1M2015-12-29$5.7M$50.6M85%
Seed$2.5M2016-07-22$12.5M$111.0M90%
Pre-Seed$523K2016-07-22$2.9M$28.9M85%
Seed$2.4M2017-02-24$12.1M$107.1M90%
Seed$3.0M2017-07-01$15.0M$133.2M90%
Series A$4.9M2017-10-24$22.4M$178.2M90%
Series A$4.4M2017-10-24$20.0M$158.7M90%
Series A$1.4M2018-08-08$6.5M$51.7M90%
Series A$2.1M2019-09-27$9.4M$74.7M90%
Series A$100K2020-05-04$455K$3.6M90%
What happened at each round

Step-up, pace versus the sector's normal cadence, and revenue/exemption moves — read straight from the reported round facts reported.

  1. Seed$1.1M2015-12-29
    • First recorded raise — entered as Seed.
    • 9 investors on this round.
  2. Seed$2.5M2016-07-22
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 2.2× larger than the prior — scaling up.
    • 36 investors on this round.
  3. Pre-Seed$523K2016-07-22
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round 4.8× smaller than the prior — bridge or down round.
    • 8 investors on this round.
  4. Seed$2.4M2017-02-24
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 4.6× larger than the prior — scaling up.
    • 16 investors on this round.
  5. Seed$3.0M2017-07-01
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round roughly the size of the prior one.
  6. Series A$4.9M2017-10-24
    • Came back fast: 4 mo vs the ~14 mo sector norm.
    • Round 1.6× larger than the prior — scaling up.
    • 64 investors on this round.
  7. Series A$4.4M2017-10-24
    • Filed alongside the prior round (same month) — likely a tranche or amendment.
    • Round roughly the size of the prior one.
    • 48 investors on this round.
  8. Series A$1.4M2018-08-08
    • Raised 9 mo later, in step with the ~14 mo sector norm.
    • Round 3.1× smaller than the prior — bridge or down round.
    • 7 investors on this round.
  9. Series A$2.1M2019-09-27
    • Raised 14 mo later, in step with the ~14 mo sector norm.
    • Round 1.4× larger than the prior — scaling up.
    • Switched to Rule 506(c) (was Rule 506(b)).
    • 31 investors on this round.
  10. Series A$100K2020-05-04
    • Came back fast: 7 mo vs the ~14 mo sector norm.
    • Round 20.7× smaller than the prior — bridge or down round.
    • Switched to Rule 506(b) (was Rule 506(c)).
    • 3 investors on this round.
Intelligence
2020 ~Q4
Modeled next raise · ~6mo cadence
$100K
Modeled next size est.range $100K$160K
0.0×
Last step-up
$3.4M/yr
Capital velocity

Predictive signals are modeled est. from this company's own cadence and step-up, plus sector benchmarks — directional, not advice. Peer set and a CSV export live in your analyst workspace.

Key people & operators

Officers, directors and promoters named in this company's public recordsreported — the people who run it (not its investors). "Also runs" counts come from name-matching across all records, so verify before acting.

PersonRoleAlso runsTied since
Yung-Ping Yeh3 other2015-12
Marcus Boehm2 other2016-07
Andrew LaFrence1 other2019-09
Murdoc Khaleghi1 other2015-12
Paul Hansen1 other2015-12
Robert Petcavich1 other2015-12
Ryan Gordon1 other2015-12
Steven Snyder1 other2015-12
Blake Anson2019-09
David Buche2017-07
Dimas Jimenez2017-02
Fabian Zanella2017-02
Kevin Gunderson2015-12
Matthew Peris2017-02
Patrick O'Shaughnessy2017-02
Sriram Nadathur2019-09
Registry & provenance

StemoniX, Inc. is an official record sourced from the U.S. Securities and Exchange Commission (SEC). U.S. data is aggregated from SEC Form D filings.

United States
Country of record
US
Jurisdiction
1663434
SEC CIK
Similar companies

Nearest neighbours across the whole database — matched on sector, stage and capital scale, and on shared operators (officers or directors named at both companies in public filings). A discovery shortlist, not a valuation cohort — verify before acting, the same way modeled figures are directional.

CompanySectorStageRaised · realValue · estWhy similar
Luminary Therapeutics, Inc.BiotechnologySeries A$14.5M$4.0Msame sector · same stage
Immutrix Therapeutics, Inc.BiotechnologySeries A$14.5M$1.4Msame sector · same stage
Adaptin Bio, Inc.BiotechnologySeries A$14.7M$4.3Msame sector · same stage
Bioscience Americas, LLCBiotechnologySeries A$15.1M$4.3Msame sector · same stage
Suono Bio, Inc.BiotechnologySeries A$14.0M$4.0Msame sector · same stage
Pirouette Medical Inc.BiotechnologySeries A$14.0M$2.5Msame sector · same stage
Elastrin Therapeutics, Inc.BiotechnologySeries A$13.3M$2.4Msame sector · same stage
Biopoly, LlcBiotechnologySeries A$13.2M$4.3Msame sector · same stage
Semantically similar

Matched by meaning, not labels — a local language model reads each company's name, sector and description and ranks the closest in that learned space. This catches look-alikes that cross sector boundaries; the structured list above explains its matches, this one trusts the text. Directional, like every modeled signal here.

CompanySectorStageValue · estMatch
Stemgenics, Inc.BiotechnologySeed$19.8M89%
Opsonix, Inc.BiotechnologySeed$55.5M89%
StemBioSys Inc.BiotechnologySeries A$43.8M88%
Applied Stemcell IncBiotechnologySeries B$754.1M87%
Valentx IncBiotechnologySeries B$78.2M85%
BioPlx, Inc.BiotechnologySeed$47.8M85%
RegenX Science Inc.BiotechnologySeries A$62.3M85%
Synthorx, Inc.BiotechnologySeries B$1.1B84%
Frequently asked
How much funding has StemoniX, Inc. raised?
StemoniX, Inc. has raised approximately $14.6M in disclosed capital across 7 recorded financing rounds, aggregated from public filings.
What is StemoniX, Inc.'s estimated valuation?
Provath's modeled valuation for StemoniX, Inc. is approximately $3.6M (modeled range $109K–$19.7M). This is an algorithmic estimate derived from round sizes and same-niche peers — not a quoted or reported figure.
What funding stage is StemoniX, Inc. at?
StemoniX, Inc.'s latest modeled financing stage is Series A. Its most recent recorded round closed around Mon May 04.
What does StemoniX, Inc. do and where is it based?
StemoniX, Inc. operates in the Biotechnology sector, based in Maple Grove.
Explore related

See where StemoniX, Inc. sits in the wider market — its sector, location and stage cohorts, each with their own leaderboards and capital-flow timelines.

Is this your company?

If you work at StemoniX, Inc., claim this profile or suggest a correction. We aggregate from public filings, so help us keep your description, website and links accurate.

Is this your company? Update your profile or add contact details — and choose exactly who can reach you. Reviewed before anything is published.